Lovelace Health Plan Chooses Elsevier / MEDai Predictive Analytic Solutions to Reduce Costs, Enhance Data Sharing and Assess Risk

Suite of Risk Navigator Products Chosen to Drive Quality Outcomes Through Predictive Analytics and Behavioral Modeling at New Mexico Health Plan

ORLANDO, Florida, April 14, 2011 - Elsevier / MEDai (www.medai.com), a leading health
information company with award-winning solutions for the improvement of care
delivery, announced today that Lovelace Health Plan in New Mexico has
purchased several products in MEDai's suite of Risk Navigator products to
drive quality outcomes through predictive analytics. Lovelace will use Risk
Navigator Clinical(R), Risk Navigator Performance(R) and Risk Navigator
Financial(R).

Lovelace chose the suite of Risk Navigator products because of
its ease of use, reliability and transparency of risk predictions,
integration of evidence-based medicine guidelines, and the speed and
thoroughness of implementation.

"We were in need of a solution that allowed us to reliably
forecast healthcare costs, identify and stratify risk in our patient
populations, identify which patients would be positively impacted by our case
and disease management programs, and enhance the patient/provider
experience," said John Cruickshank, chief medical officer, Lovelace Health
Plan. "The suite of Risk Navigator products we have selected will allow us to
focus on member and clinician engagement, enhance communication, continually
measure and improve quality of care, and manage costs."

Risk Navigator Clinical applies evidence-based clinical rule
sets and advanced mathematical process to claims, membership and other data
to identify high-risk members. Lovelace will utilize Risk Navigator Clinical
to improve its population risk and member disease management. At the
population level, Lovelace will better understand what conditions are driving
costs within the health plan and what the risk profile is of the population
as a whole. At the member level, it will be utilized to show how to manage
high-risk conditions (i.e. diabetes, asthma, coronary artery disease, etc.).
Clinicians and administrators can then use these clinically based forecasts
to allocate resources efficiently and intervene before adverse outcomes occur
and unnecessary dollars are spent.

Lovelace will also use Risk Navigator Clinical to improve
engagement with clinicians by giving them access to member history and
compliance information. Risk Navigator Clinical will allow clinicians to see
a member's compliance with evidence-based medicine guidelines. If a clinician
receives a report that shows his patients have a 50% compliance rate, that
clinician now has the ability to engage with his patients based on the
information provided by Lovelace and potentially improve outcomes for that
patient.

Risk Navigator Performance provides retrospective and
prospective profiling of providers and facilities, and compares provider and
facility performance against national and regional benchmarks. Lovelace will
use Risk Navigator Performance to view provider profiles internally by
focusing on quality and evidence-based medicine guideline compliance rates.

Risk Navigator Financial supports actuarial and underwriting
analysis and reporting by leveraging clinical risk information and cost
predictions. Risk Navigator Financial will allow Lovelace to better identify
and assess the risk associated with an employer group at the time of renewal.
Additionally, Lovelace will be able to look at the risk assessment by
categories of eligibility for its Medicaid population.

"Health systems are faced with the task to ensure a high
quality of care while also managing costs," said Clayton Ramsey, chief
operating officer, Elsevier / MEDai. "MEDai's predictive analytic tools will
allow Lovelace to identify costly populations, assess risk and improve
provider information sharing ultimately improving quality outcomes and
lowering healthcare costs."

For more information, please visit www.medai.com or
call +1-800-446-3324.

About Elsevier / MEDai

Elsevier/MEDai, Inc. is a leading health information company
offering award-winning solutions for the improvement of healthcare delivery.
Utilizing cutting-edge technology, payers and care management organizations
are able to predict patients at risk, identify cost drivers for their
high-risk population, forecast future health plan costs, evaluate patient
patterns over time, and improve outcomes. For more information on
Elsevier/MEDai, visit www.medai.com. Its parent company, Elsevier
(www.elsevier.com), is a world-leading publisher of scientific,
technical and medical information products and services, with more than
7,000 employees in over 70 offices across 24 countries.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com), SciVerse Scopus
(www.scopus.com), Reaxys (www.reaxys.com), MD Consult
(www.mdconsult.com) and Nursing Consult (www.nursingconsult.com
), which enhance the productivity of science and health professionals, and
the SciVal suite (www.scival.com) and MEDai's Pinpoint Review
(www.medai.com), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier
(www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact:
    Tom Reller
    VP, Global Corporate Relations, Elsevier
    +1-215-239-3508
    T.Reller@Elsevier.com

.